Michael Devitt

528 total citations
31 papers, 148 citations indexed

About

Michael Devitt is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Michael Devitt has authored 31 papers receiving a total of 148 indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Pulmonary and Respiratory Medicine, 19 papers in Oncology and 9 papers in Molecular Biology. Recurrent topics in Michael Devitt's work include Prostate Cancer Treatment and Research (10 papers), Cancer Immunotherapy and Biomarkers (6 papers) and Bladder and Urothelial Cancer Treatments (5 papers). Michael Devitt is often cited by papers focused on Prostate Cancer Treatment and Research (10 papers), Cancer Immunotherapy and Biomarkers (6 papers) and Bladder and Urothelial Cancer Treatments (5 papers). Michael Devitt collaborates with scholars based in United States, Spain and Greece. Michael Devitt's co-authors include Michael E. Williams, Craig A. Portell, Surabhi Palkimas, Paul R. Kunk, Bethany J. Horton, Hillary S. Maitland, Robert Dreicer, Zachery R. Reichert, Elisabeth I. Heath and Sarah Yentz and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Annals of Oncology.

In The Last Decade

Michael Devitt

25 papers receiving 144 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Michael Devitt United States 6 63 58 43 43 33 31 148
Yasuhiro Taniguchi Japan 10 38 0.6× 40 0.7× 74 1.7× 23 0.5× 11 0.3× 34 224
Claire Blanchard‐Delaunay France 7 92 1.5× 40 0.7× 54 1.3× 19 0.4× 31 0.9× 10 197
Vahid Asnafi France 4 23 0.4× 63 1.1× 63 1.5× 50 1.2× 16 0.5× 8 165
Joel Wight Australia 8 43 0.7× 104 1.8× 24 0.6× 58 1.3× 21 0.6× 22 157
Anupkumar George Australia 4 54 0.9× 100 1.7× 19 0.4× 65 1.5× 22 0.7× 6 143
H M Amin United States 6 16 0.3× 48 0.8× 75 1.7× 45 1.0× 29 0.9× 6 331
María Perera Spain 7 50 0.8× 23 0.4× 48 1.1× 9 0.2× 19 0.6× 14 167
Enrica Gamba Italy 3 52 0.8× 61 1.1× 19 0.4× 34 0.8× 15 0.5× 3 119
C-M Wendtner Germany 5 84 1.3× 57 1.0× 64 1.5× 16 0.4× 6 0.2× 5 148
Brett T. Brinker United States 5 46 0.7× 20 0.3× 65 1.5× 41 1.0× 23 0.7× 5 133

Countries citing papers authored by Michael Devitt

Since Specialization
Citations

This map shows the geographic impact of Michael Devitt's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael Devitt with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael Devitt more than expected).

Fields of papers citing papers by Michael Devitt

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael Devitt. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael Devitt. The network helps show where Michael Devitt may publish in the future.

Co-authorship network of co-authors of Michael Devitt

This figure shows the co-authorship network connecting the top 25 collaborators of Michael Devitt. A scholar is included among the top collaborators of Michael Devitt based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael Devitt. Michael Devitt is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Smith, David C., Elisabeth I. Heath, Frank C. Cackowski, et al.. (2025). Multicenter Phase II Study of Olaparib and the ATR Inhibitor Ceralasertib in Metastatic Castration-Resistant Prostate Cancer (TRAP). JCO Precision Oncology. 9(9). e2500457–e2500457.
2.
Batchala, Prem P., Robert Dreicer, Michael Devitt, et al.. (2025). Incidental Brain Metastases From Prostate Cancer Diagnosed With PSMA PET/CT and MRI: A Case Series and Literature Review. The Prostate. 85(9). 841–849. 1 indexed citations
3.
Autio, Karen A., Christos E. Kyriakopoulos, Han Xiao, et al.. (2025). A phase 1b/2 study of intermittent talazoparib plus temozolomide in patients with metastatic castration-resistant prostate cancer and no mutations in DNA damage response genes. Investigational New Drugs. 43(4). 924–932.
4.
Devitt, Michael, et al.. (2024). Impact of DPP4 Inhibition on Survival in Patients With Metastatic Renal Cell Carcinoma and Type 2 Diabetes Mellitus. Clinical Genitourinary Cancer. 22(5). 102173–102173. 1 indexed citations
5.
Devitt, Michael, et al.. (2024). Clinical Management of Advanced Prostate Cancer: Where Does Radiopharmaceutical Therapy Fit in the Treatment Algorithm?. Journal of Nuclear Medicine. 65(5). 679–685. 2 indexed citations
6.
Devitt, Michael, et al.. (2024). KPG-121, a novel cereblon modulator, in patients with metastatic castration resistant prostate cancer: Results of a phase I multiple ascending dose study.. Journal of Clinical Oncology. 42(16_suppl). e17054–e17054. 1 indexed citations
7.
Devitt, Michael, et al.. (2024). Impact of Renin-Angiotensin System Inhibitors on Response to PD1/L1 Inhibitors in Patients With Metastatic Renal Cell Carcinoma. Clinical Genitourinary Cancer. 23(1). 102256–102256. 2 indexed citations
8.
Skelton, William Paul, et al.. (2024). When You Get to the Fork in the Road, Take It: The Challenges in Managing Patients With Advanced Prostate Cancer. JCO Oncology Practice. 21(4). 467–475.
9.
Autio, Karen A., Christos E. Kyriakopoulos, Han Xiao, et al.. (2023). A phase Ib/II study of intermittent talazoparib plus temozolomide in patients with metastatic castration-resistant prostate cancer (mCRPC) and no mutations in DNA damage repair (DDR).. Journal of Clinical Oncology. 41(16_suppl). e17036–e17036. 2 indexed citations
10.
Reichert, Zachery R., Michael Devitt, Joshi J. Alumkal, et al.. (2022). Targeting resistant prostate cancer, with or without DNA repair defects, using the combination of ceralasertib (ATR inhibitor) and olaparib (the TRAP trial).. Journal of Clinical Oncology. 40(6_suppl). 88–88. 17 indexed citations
11.
Reichert, Zachery R., Stephanie Daignault, Benjamin A. Teply, Michael Devitt, & Elisabeth I. Heath. (2020). Targeting resistant prostate cancer with ATR and PARP inhibition (TRAP trial): A phase II study.. Journal of Clinical Oncology. 38(6_suppl). TPS254–TPS254. 7 indexed citations
12.
Devitt, Michael & Robert Dreicer. (2019). Evolving Role of Genomics in Genitourinary Neoplasms. Acta Medica Academica. 48(1). 68–68. 1 indexed citations
13.
Dimou, Anastasios, Terry L. Ng, A. Chalmers, et al.. (2018). OA12.06 Mutational Landscape of BRAF V600E Positive Lung Cancer Patients Following BRAF Directed Therapy Failure. Journal of Thoracic Oncology. 13(10). S349–S349.
14.
Kunk, Paul R., Surabhi Palkimas, Michael Devitt, et al.. (2018). Risk of Major Bleeding with Ibrutinib. Clinical Lymphoma Myeloma & Leukemia. 18(11). 755–761. 48 indexed citations
15.
Devitt, Michael, Ralph Abraham, Bethany J. Horton, et al.. (2018). Risk of CNS adverse events (CNS-AEs) for patients with non-small cell lung cancer (NSCLC) and melanoma brain metastases (BM) treated with CNS radiation (CNS-RT) and immune checkpoint inhibitors (CPIs).. Journal of Clinical Oncology. 36(15_suppl). 2010–2010. 1 indexed citations
16.
Devitt, Michael. (2013). Diagnosis of Stable Ischemic Heart Disease: Recommendations from the ACP. American family physician. 88(7). 469–470. 1 indexed citations
17.
Devitt, Michael. (2013). ACP Updates Guideline on Oral Pharmacologic Treatments for Type 2 Diabetes Mellitus. American family physician. 87(2). 140–144. 1 indexed citations
18.
Devitt, Michael. (2013). ACR Publishes Guidelines for Pharmacologic and Nonpharmacologic Treatment of Gout. American family physician. 88(6). 408–412.
19.
Devitt, Michael. (2012). AAN, AANEM, and AAPMR Publish Guideline for Treatment of Painful Diabetic Neuropathy. American family physician. 86(5). 469–470. 3 indexed citations
20.
Devitt, Michael. (2012). AAP Expands Recommendations on SIDS and Other Sleep-Related Deaths. American family physician. 85(9). 918–923. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Yasuhiro Taniguchi Breakdown of academic impact, for papers by Claire Blanchard‐Delaunay Breakdown of academic impact, for papers by Vahid Asnafi Breakdown of academic impact, for papers by Joel Wight Breakdown of academic impact, for papers by Anupkumar George Breakdown of academic impact, for papers by H M Amin Breakdown of academic impact, for papers by María Perera Breakdown of academic impact, for papers by Enrica Gamba Breakdown of academic impact, for papers by C-M Wendtner Breakdown of academic impact, for papers by Brett T. Brinker
Rankless by CCL
2026